

# Eric G Meissner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4904592/publications.pdf>

Version: 2024-02-01

41  
papers

1,487  
citations

516710

16  
h-index

315739

38  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2536  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 804.	7.4	265
2	Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1232.	7.4	186
3	Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. <i>Journal of Clinical Investigation</i> , 2014, 124, 3352-3363.	8.2	179
4	Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. <i>Lancet, The</i> , 2015, 385, 1107-1113.	13.7	148
5	Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1 infected patients. <i>Hepatology</i> , 2015, 61, 790-801.	7.3	128
6	Simeprevir treatment of advanced liver fibrosis in HIV and HCV infected adults: results of a 6-month open-label safety trial. <i>Liver International</i> , 2016, 36, 1783-1792.	3.9	79
7	IFNL4 <sup>rs36959</sup> G Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin. <i>Journal of Infectious Diseases</i> , 2014, 209, 1700-1704.	4.0	74
8	IFNL4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. <i>Journal of Immunology</i> , 2017, 199, 3808-3820.	0.8	55
9	Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection. <i>Annals of Internal Medicine</i> , 2015, 163, 899-907.	3.9	53
10	Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. <i>Hepatology Communications</i> , 2017, 1, 586-594.	4.3	36
11	Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 456-462.	1.1	34
12	Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. <i>PLoS ONE</i> , 2015, 10, e0133236.	2.5	33
13	Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. <i>BioMed Research International</i> , 2017, 1-8.	1.9	29
14	Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. <i>Antiviral Research</i> , 2017, 144, 281-285.	4.1	26
15	Cardiovascular Disease, Statins, and HIV. <i>Journal of Infectious Diseases</i> , 2016, 214, S83-S92.	4.0	25
16	Update in HIV hepatitis C virus coinfection in the direct acting antiviral era. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 120-127.	2.3	20
17	Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination. <i>Vaccine</i> , 2016, 34, 1945-1955.	3.8	13
18	Association of Substance Use With Hospitalization and Virologic Suppression in a Southern Academic HIV Clinic. <i>American Journal of the Medical Sciences</i> , 2018, 355, 553-558.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis. <i>Hepatology International</i> , 2016, 10, 937-946.	4.2	12
20	Increasing Prevalence of Chronic Hepatitis C Virus Infection in a Southern Academic Obstetrical Clinic. <i>Southern Medical Journal</i> , 2019, 112, 325-330.	0.7	9
21	Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 118-124.	2.0	8
22	Across state lines: Fulminant <i>Babesia microti</i> infection in a liver transplant recipient. <i>Transplant Infectious Disease</i> , 2017, 19, e12741.	1.7	7
23	Longitudinal analysis of serum microRNAs as predictors of cirrhosis regression during treatment of hepatitis B virus infection. <i>Liver International</i> , 2020, 40, 1693-1700.	3.9	7
24	Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. <i>Viruses</i> , 2021, 13, 1090.	3.3	7
25	Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. <i>Journal of Viral Hepatitis</i> , 2019, 26, 323-328.	2.0	6
26	Cardiovascular Disease Risk Management in Persons With HIV: Does Clinician Specialty Matter?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa361.	0.9	6
27	Patient-Provider Text Messaging and Video Calling Among Case-Managed Patients Living With HIV: Formative Acceptability and Feasibility Study. <i>JMIR Formative Research</i> , 2021, 5, e22513.	1.4	6
28	Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 142-148.	3.1	4
29	Perspectives of HIV specialists and cardiologists on the specialty referral process for people living with HIV: a qualitative descriptive study. <i>BMC Health Services Research</i> , 2022, 22, 623.	2.2	4
30	Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. <i>BMC Infectious Diseases</i> , 2020, 20, 929.	2.9	3
31	Identification of Priority Areas for Increased Testing Using Geospatial Mapping of Incident HIV Cases Near Charleston, South Carolina. <i>Infectious Diseases: Research and Treatment</i> , 2019, 12, 117863371987075.	1.7	2
32	IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 184-188.	1.1	2
33	Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1614-1623.	2.0	2
34	Continued value in understanding viral kinetic decline during interferon-free therapy for HCV. <i>Liver International</i> , 2015, 35, 295-296.	3.9	1
35	On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-4.	0.5	1
36	Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. <i>Antiviral Research</i> , 2017, 138, 79-85.	4.1	1

#	ARTICLE	IF	CITATIONS
37	The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?. <i>Clinical Infectious Diseases</i> , 2018, 67, 878-880.	5.8	1
38	295. South Carolina Hepatitis C Telehealth Initiative (SCHTI): Increasing Access to HCV Care. <i>Open Forum Infectious Diseases</i> , 2019, 6, S160-S160.	0.9	1
39	Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8+ T-Cell Function. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab118.	0.9	1
40	460. Point-of-Care, In-Home SARS-CoV-2 IgG Antibody Testing to Assess Seroprevalence in At-Risk Health Care Workers. <i>Open Forum Infectious Diseases</i> , 2020, 7, S297-S297.	0.9	0
41	Self-administered, remote assessment of SARS-CoV-2 seroprevalence in health care workers. <i>American Journal of the Medical Sciences</i> , 2022, 364, 281-288.	1.1	0